Want to see HK:0512 full AI Analyst Report?
Grand Pharmaceutical Group Limited (0512) Ratios
Grand Pharmaceutical Group Limited Ratios
HK:0512's free cash flow for Q2 2026 was $-132.92M. For the 2026 fiscal year, HK:0512's free cash flow was decreased by $-184.39M and operating cash flow was $51.48M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.14 | 1.22 | 1.22 | 1.07 | 1.22 |
| Quick Ratio | 0.93 | 1.01 | 0.98 | 0.86 | 1.02 |
| Cash Ratio | 0.16 | 0.20 | 0.23 | 0.22 | 0.32 |
| Solvency Ratio | 0.18 | 0.35 | 0.31 | 0.30 | 0.36 |
| Operating Cash Flow Ratio | 0.21 | 0.29 | 0.42 | 0.30 | 0.38 |
| Short-Term Operating Cash Flow Coverage | 0.53 | 0.61 | 1.05 | 0.59 | 1.00 |
| Net Current Asset Value | $ -1.68B | $ -440.31M | $ -228.66M | $ -1.28B | $ -835.58M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.17 | 0.18 | 0.15 | 0.20 | 0.17 |
| Debt-to-Equity Ratio | 0.28 | 0.27 | 0.22 | 0.32 | 0.27 |
| Debt-to-Capital Ratio | 0.22 | 0.21 | 0.18 | 0.24 | 0.21 |
| Long-Term Debt-to-Capital Ratio | 0.10 | 0.07 | 0.06 | 0.08 | 0.10 |
| Financial Leverage Ratio | 1.60 | 1.52 | 1.49 | 1.58 | 1.57 |
| Debt Service Coverage Ratio | 0.70 | 0.91 | 1.00 | 0.79 | 1.23 |
| Interest Coverage Ratio | 6.42 | 12.05 | 12.98 | 18.31 | 21.71 |
| Debt to Market Cap | 0.17 | 0.26 | 0.24 | 0.27 | 0.16 |
| Interest Debt Per Share | 1.39 | 1.32 | 1.03 | 1.30 | 1.05 |
| Net Debt to EBITDA | 1.51 | 0.92 | 0.70 | 0.98 | 0.61 |
| Profitability Margins | |||||
| Gross Profit Margin | 55.20% | 57.86% | 61.96% | 62.24% | 61.03% |
| EBIT Margin | 14.38% | 24.77% | 24.45% | 28.22% | 32.16% |
| EBITDA Margin | 19.12% | 29.09% | 28.17% | 32.35% | 36.11% |
| Operating Profit Margin | 8.49% | 18.65% | 25.29% | 26.33% | 23.48% |
| Pretax Profit Margin | 12.16% | 24.49% | 22.26% | 26.32% | 32.40% |
| Net Profit Margin | 10.10% | 21.20% | 17.85% | 21.75% | 27.94% |
| Continuous Operations Profit Margin | 10.13% | 21.18% | 18.00% | 21.94% | 27.97% |
| Net Income Per EBT | 83.05% | 86.54% | 80.20% | 82.62% | 86.24% |
| EBT Per EBIT | 143.32% | 131.32% | 88.02% | 99.97% | 138.01% |
| Return on Assets (ROA) | 4.57% | 9.88% | 8.35% | 9.30% | 11.41% |
| Return on Equity (ROE) | 7.29% | 14.98% | 12.40% | 14.71% | 17.94% |
| Return on Capital Employed (ROCE) | 5.25% | 11.79% | 15.87% | 15.82% | 13.03% |
| Return on Invested Capital (ROIC) | 3.82% | 8.71% | 11.25% | 10.95% | 9.89% |
| Return on Tangible Assets | 5.58% | 11.66% | 9.27% | 10.56% | 12.74% |
| Earnings Yield | 4.51% | 14.69% | 13.40% | 12.76% | 10.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.59 | 4.18 | 4.68 | 4.33 | 4.00 |
| Payables Turnover | 3.03 | 4.03 | 3.01 | 4.14 | 4.56 |
| Inventory Turnover | 3.71 | 3.58 | 2.88 | 2.69 | 3.00 |
| Fixed Asset Turnover | 2.55 | 3.04 | 2.64 | 2.43 | 2.26 |
| Asset Turnover | 0.45 | 0.47 | 0.47 | 0.43 | 0.41 |
| Working Capital Turnover Ratio | 10.06 | 8.51 | 12.26 | 11.63 | 7.72 |
| Cash Conversion Cycle | 118.51 | 98.74 | 83.31 | 131.51 | 132.93 |
| Days of Sales Outstanding | 140.68 | 87.34 | 78.01 | 84.24 | 91.25 |
| Days of Inventory Outstanding | 98.44 | 101.96 | 126.54 | 135.50 | 121.69 |
| Days of Payables Outstanding | 120.61 | 90.56 | 121.23 | 88.23 | 80.01 |
| Operating Cycle | 239.12 | 189.30 | 204.55 | 219.74 | 212.94 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.43 | 0.54 | 0.69 | 0.54 | 0.60 |
| Free Cash Flow Per Share | 0.22 | 0.36 | 0.55 | 0.07 | 0.42 |
| Dividend Paid and CapEx Coverage Ratio | 0.92 | 1.24 | 2.44 | 0.93 | 2.09 |
| Capital Expenditure Coverage Ratio | 2.07 | 3.05 | 4.87 | 1.15 | 3.38 |
| Operating Cash Flow Coverage Ratio | 0.32 | 0.43 | 0.71 | 0.43 | 0.58 |
| Operating Cash Flow to Sales Ratio | 0.12 | 0.16 | 0.23 | 0.20 | 0.25 |
| Free Cash Flow Yield | 2.82% | 7.59% | 13.74% | 1.51% | 6.52% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 22.43 | 6.81 | 7.46 | 7.84 | 9.54 |
| Price-to-Sales (P/S) Ratio | 2.24 | 1.44 | 1.33 | 1.70 | 2.67 |
| Price-to-Book (P/B) Ratio | 1.62 | 1.02 | 0.93 | 1.15 | 1.71 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 35.50 | 13.17 | 7.28 | 66.29 | 15.33 |
| Price-to-Operating Cash Flow Ratio | 18.32 | 8.86 | 5.79 | 8.50 | 10.80 |
| Price-to-Earnings Growth (PEG) Ratio | -0.45 | 0.23 | -0.88 | -0.59 | 0.31 |
| Enterprise Value Multiple | 13.22 | 5.88 | 5.43 | 6.25 | 7.99 |
| Enterprise Value | 31.05B | 19.91B | 16.10B | 19.32B | 24.81B |
| EV to EBITDA | 13.22 | 5.88 | 5.43 | 6.25 | 7.99 |
| EV to Sales | 2.53 | 1.71 | 1.53 | 2.02 | 2.89 |
| EV to Free Cash Flow | 40.09 | 15.60 | 8.35 | 78.62 | 16.59 |
| EV to Operating Cash Flow | 20.69 | 10.49 | 6.64 | 10.08 | 11.69 |
| Tangible Book Value Per Share | 3.49 | 3.63 | 3.71 | 3.25 | 3.17 |
| Shareholders’ Equity Per Share | 4.86 | 4.70 | 4.32 | 3.99 | 3.77 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.17 | 0.14 | 0.19 | 0.17 | 0.14 |
| Revenue Per Share | 3.51 | 3.33 | 3.00 | 2.70 | 2.42 |
| Net Income Per Share | 0.35 | 0.70 | 0.54 | 0.59 | 0.68 |
| Tax Burden | 0.83 | 0.87 | 0.80 | 0.83 | 0.86 |
| Interest Burden | 0.85 | 0.99 | 0.91 | 0.93 | 1.01 |
| Research & Development to Revenue | 0.04 | 0.05 | 0.05 | 0.06 | 0.04 |
| SG&A to Revenue | 0.42 | 0.40 | 0.12 | 0.11 | 0.11 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.21 | 0.67 | 1.29 | 0.92 | 0.88 |
Currency in HKD
